Incyte (INCY) Non-Current Assets (2010 - 2026)
Incyte (INCY) reported Non-Current Assets of $1.9 billion for Q1 2026, down 17.27% on a YoY basis from $2.2 billion in Q1 2025, and down 4.1% quarter-over-quarter from $1.9 billion in Q4 2025.
Incyte (INCY) Non-Current Assets (2010 - 2026) Analysis & Trends
Incyte has reported Non-Current Assets for 17 years, with the latest figure at $1.9 billion in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets fell 17.27% year-over-year to $1.9 billion; the trailing twelve-month figure through Mar 2026 stood at $8.0 billion (down 8.31% YoY), and the FY2025 full-year result was $1.9 billion, down 12.3% from the prior year.
- Non-Current Assets for Q1 2026 stood at $1.9 billion, down from $1.9 billion in the prior quarter.
- The five-year high for Non-Current Assets was $2.3 billion in Q1 2024, with the low at $1.7 billion in Q3 2022.
- Historically, Non-Current Assets has averaged $2.0 billion across 5 years, with a median of $2.0 billion in 2023.
- Annual changes were most pronounced in 2022 — Non-Current Assets jumped 45.78% — and 2026, when it declined 17.27%.
- Incyte's Non-Current Assets stood at $1.7 billion in 2022, then grew by 22.23% to $2.1 billion in 2023, then rose by 3.21% to $2.2 billion in 2024, then declined by 12.3% to $1.9 billion in 2025, then declined by 4.1% to $1.9 billion in 2026.
- The last three Non-Current Assets figures came in at $1.9 billion (Q1 2026), $1.9 billion (Q4 2025), and $2.1 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | 1.85 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.85 Bn |
| Dec 31, 2025 | 1.93 Bn |
| Sep 30, 2025 | 2.05 Bn |
| Jun 30, 2025 | 2.18 Bn |
| Mar 31, 2025 | 2.24 Bn |
| Dec 31, 2024 | 2.21 Bn |
| Sep 30, 2024 | 2.20 Bn |
| Jun 30, 2024 | 2.09 Bn |
| Mar 31, 2024 | 2.29 Bn |
| Dec 31, 2023 | 2.14 Bn |
| Sep 30, 2023 | 1.99 Bn |
| Jun 30, 2023 | 1.94 Bn |
| Mar 31, 2023 | 1.83 Bn |
| Dec 31, 2022 | 1.75 Bn |
| Sep 30, 2022 | 1.69 Bn |
| Jun 30, 2022 | 1.69 Bn |
| Mar 31, 2022 | 1.77 Bn |
| Dec 31, 2021 | 1.81 Bn |
| Sep 30, 2021 | 1.28 Bn |
| Jun 30, 2021 | 1.28 Bn |